Valion Bio, Inc. Common Stock (NASDAQ:VBIO) Sees Significant Increase in Short Interest

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) was the target of a large increase in short interest during the month of June. As of June 15th, there was short interest totaling 260,360 shares, an increase of 73.8% from the May 31st total of 149,795 shares. Based on an average trading volume of 693,061 shares, the days-to-cover ratio is presently 0.4 days. Currently, 8.3% of the shares of the stock are short sold.

Valion Bio, Inc. Common Stock Trading Down 5.5%

Shares of NASDAQ VBIO traded down $0.03 during trading hours on Thursday, reaching $0.49. The stock had a trading volume of 29,721 shares, compared to its average volume of 272,099. Valion Bio, Inc. Common Stock has a 52-week low of $0.46 and a 52-week high of $5.60. The firm has a market cap of $1.57 million, a price-to-earnings ratio of -0.07 and a beta of 1.82. The business’s fifty day moving average price is $0.82 and its two-hundred day moving average price is $1.03. The company has a current ratio of 3.31, a quick ratio of 3.02 and a debt-to-equity ratio of 0.62.

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) last posted its earnings results on Thursday, May 14th. The company reported ($2.23) EPS for the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Valion Bio, Inc. Common Stock in a research report on Monday, April 20th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

About Valion Bio, Inc. Common Stock

Tivic Health Systems is a commercial-stage medical technology company that develops and markets non-drug, neuromodulation-based therapies for nasal and sinus health. The company’s solutions are designed to alleviate sinus pain, pressure and congestion through gentle microcurrent and vibration stimulation. By targeting the underlying nerve pathways in the nasal passages, Tivic Health aims to provide an alternative to over-the-counter and prescription medications without introducing systemic side effects.

The flagship product, ClearUP™ Sinus Pain Relief, is an FDA-cleared, hand-held device intended for home use.